Diabetic Macular Edema (DME) Clinical Trials

11 recruiting

Diabetic Macular Edema (DME) Trials at a Glance

12 actively recruiting trials for diabetic macular edema (dme) are listed on ClinicalTrialsFinder across 6 cities in 7 countries. The largest study group is Phase 3 with 3 trials, with the heaviest enrollment activity in Redlands, The Woodlands, and Carmel. Lead sponsors running diabetic macular edema (dme) studies include EyePoint Pharmaceuticals, Inc., BioCryst Pharmaceuticals, and Bio-Thera Solutions.

Browse diabetic macular edema (dme) trials by phase

Treatments under study

About Diabetic Macular Edema (DME) Clinical Trials

Looking for clinical trials for Diabetic Macular Edema (DME)? There are currently 11 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Diabetic Macular Edema (DME) trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Diabetic Macular Edema (DME) clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 112 of 12 trials

Recruiting

DATA-INSIGHT is a Project That Looks at Health Data in Germany to Find Out How Many Patients Suffer From Eye Disease. The Project Also Explores New Ways to Collect and Use Publicly Available Healthcare Information.

Neovascular Age-related Macular Degeneration (nAMD); Diabetic Macular Edema (DME); Retinal Vein Occlusion (RVO)
Bayer50,000 enrolled1 locationNCT07308639
Recruiting
Not Applicable

Biomarkers in Diabetic Retinopathy Treated With Faricimab vs Biosimilar Ranibizumab

Diabetic Retinopathy (DR)Diabetic Macular Edema (DME)
Osijek University Hospital100 enrolled1 locationNCT07520045
Recruiting
Phase 3

COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME

Diabetic Macular Edema (DME)Diabetic Macular EdemaDME
EyePoint Pharmaceuticals, Inc.240 enrolled39 locationsNCT07449936
Recruiting
Phase 3

CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME

Diabetic Macular Edema (DME)Diabetic Macular EdemaDME
EyePoint Pharmaceuticals, Inc.240 enrolled38 locationsNCT07449923
Recruiting
Phase 3

Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Diabetic Macular Edema

Diabetic Macular Edema (DME)
Bio-Thera Solutions406 enrolled50 locationsNCT07515079
Recruiting
Phase 4

Study Evaluating the Efficacy and Safety of Chloroprocaine HCl Ophthalmic Gel 3% vs Proparacaine Ophthalmic Solution 0.5% Plus Subconjunctival Lidocaine in Patients Undergoing Intravitreal Injections

Diabetic Macular Edema (DME)
Harrow Inc236 enrolled1 locationNCT07456826
Recruiting
Early Phase 1

Safety and Efficacy Evaluation of LX111 Gene Therapy in DME Patients

Diabetic Macular Edema (DME)
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine32 enrolled2 locationsNCT07362927
Recruiting
Phase 1

A Study of Avoralstat In Participants With Diabetic Macular Edema

Diabetic Macular Edema (DME)
BioCryst Pharmaceuticals9 enrolled8 locationsNCT07228559
Recruiting
Phase 4

High Dose Aflibercept in Diabetic Macular Edema in Patients With Previous Vitrectomy

Diabetic Macular Edema (DME)
Retina Consultants of Orange County15 enrolled1 locationNCT06662994
Recruiting
Not Applicable

Impact of Intravitreal Faricimab on Renal Function in Diabetic Patients

Diabetic Macular Edema (DME)Renal Function Disorder
University Hospital, Alexandroupolis60 enrolled2 locationsNCT06929507
Recruiting

Investigating the Metabolic and Lipidomic Profiles That Are Associated With Varying Grades of Diabetic Maculopathy and Retinopathy in South Wales

Diabetic Retinopathy (DR)Diabetic Retinopathy Associated With Type 2 Diabetes MellitusDiabetic Macular Edema (DME)
Hywel Dda Health Board120 enrolled1 locationNCT06914778
Recruiting
Phase 2

A Phase 2 Study to Evaluate the Efficacy and Safety of ENN0403 in Subjects with DME

Diabetic Macular Edema (DME)
EnnovaBio60 enrolled1 locationNCT06708260